Kai Pharmaceuticals, Inc.

Kanad Das

Qun Yin

Derek Maclean

Felix D Karim

Amos Baruch

Felix Karim

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X-X-X-X-X-X-X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Therapeutic agents for reducing parathyroid hormone levels

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X&#x2014;Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Growing community of inventors

San Francisco, CA, United States of America

Kanad Das